This study will inform on long-term real-world safety and effectiveness of tisagenlecleucel. The primary objective is to evaluate the long-term safety and the risk of secondary malignancies in patients with B lymphocyte malignancies treated with tisagenlecleucel in a real-world setting. The main secondary objective is to evaluate the longterm effectiveness of tisagenlecleucel.
All participants enrolled in this study will be followed up for 15 years from the time of Kymriah® infusion.
Age
0–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients who receive tisagenlecleucel infusion in the commercial setting, treated under a managed access program or other pathway, e.g., when product was manufactured for the commercial setting but turned out to be out of specification (OOS).
2. Consented to data collection.
You may not be if
1\. Patients who are enrolled or will be enrolled in the Novartis long term follow-up protocol CCTL019A2205B.
Clareo Health | Long-term Follow up Local Registry Study of Kymriah in South Korea
